[1]刘纪营,金 洁,管 生,等.肝功能状态对晚期肝癌介入治疗生存期的影响[J].介入放射学杂志,2013,(03):247-250.
　LIU Ji? ying,JIN Jie,GUAN Sheng,et al.The effect of hepatic function status on the survival time in patients with advanced hepatocellular carcinoma after transcatheter arterial chemoembolization[J].journal interventional radiology,2013,(03):247-250.
点击复制

肝功能状态对晚期肝癌介入治疗生存期的影响()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2013年03期
页码:
247-250
栏目:
临床研究
出版日期:
2013-03-25

文章信息/Info

Title:
The effect of hepatic function status on the survival time in patients with advanced hepatocellular carcinoma after transcatheter arterial chemoembolization
作者:
刘纪营;  金 洁;  管 生;  马 南; 李明省; 胡小波; 陈 振;  刘 朝;  王子博
Author(s):
LIU Ji?蛳 ying;  JIN Jie;  GUAN Sheng;  MA Nan;  LI Ming?蛳 xing;  HU Xiao?蛳 bo;  CHEN Zhen;  LIU Chao;  WANG Zi?蛳 bo.
Department of Interventional Radiography， the First Affiliated Hospital of Zhengzhou University， Zhengzhou， Henan Province 450052， China
关键词:
【关键词】 肝细胞癌;  肝动脉化疗栓塞术;  生存期;  肝功能;  Child-Pugh分级
文献标志码:
A
摘要:
【摘要】 目的 探讨不同肝功能Child?蛳 Pugh分级对晚期肝癌（BCLC?蛳 C）TACE治疗生存期的影响。方法 回顾性分析TACE治疗的晚期肝癌患者74例。根据术前Child?蛳 Pugh分级将患者分成Child?蛳 Pugh A级和B级，Child?蛳 Pugh A级患者62例，B级患者12例，术后随访。依据Child?蛳 Pugh分级进行相关性生存分析。结果 Child?蛳 Pugh A级3、6、9、12和24个月生存率分别为85%、60%、31%、17%和11%，而Child?蛳 Pugh B级生存率分别为33%、17%、17%、8%和0%。全组患者中位生存期8.2个月。Child?蛳 Pugh A与B级中位生存期分别为8.5、2.5个月（P = 0.002）。结论 Child?蛳 Pugh A级肝功能进展期肝癌患者，从TACE治疗中能够取得生存获益。

参考文献/References:

［1］ Nishikawa H， Osaki Y， Kita R， et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan［J］. Cancers （Basel）， 2012： 165 ?蛳 183.［2］ Yoo DJ， Kim KM， Jin YJ， et al. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma： does transarterial chemoembolization improve survival in these patients？［J］. J Gastroenterol Hepatol， 2011， 26： 145 ?蛳 154.［3］ Chung GE， Lee JH， Kim HY， et al. Transarterial chemoemboli?蛳 zation can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival［J］. Radiology， 2011， 258： 627 ?蛳 634.［4］ Kim KM， Kim JH， Park IS， et al. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion［J］. J Gastroenterol Hepatol， 2009， 24： 806 ?蛳 814.［5］ Pinter M， Hucke F， Graziadei I， et al. Advanced?蛳 Stage hepatocellular carcinoma： transarterial chemoembolization versus sorafenib［J］. Radiology， 2012， 263： 590 ?蛳 599.［6］ Huang YS， Chiang JH， Wu JC， et al. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma： predictive value of the monoethylglycinexylidide test［J］. Am J Gastroenterol， 2002， 97： 1223 ?蛳 1227.［7］ Cheng AL， Kang YK， Chen Z， et al. Efficacy and safety of sorafenib in patients in the Asia?蛳 Pacific region with advanced hepatocellular carcinoma： a phase Ⅲ randomised， double?蛳 blind， placebo?蛳 controlled trial［J］. Lancet Oncol， 2009， 10： 25 ?蛳 34.［8］ Llovet JM， Ricci S， Mazzaferro V， et al. Sorafenib in advanced hepatocellular carcinoma［J］. N Engl J Med， 2008， 359： 378 ?蛳 390.［9］ Ministry of Health of the People’s Republic of China. Diagnosis，management， and treatment of hepatocellular carcinoma［J］. J Clin Hepatol， 2011， 27： 1141 ?蛳 1159.［10］ Qu XD， Chen GS， Wang JH， et al. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma［J］. BMC Cancer， 2012， 12： 263.［11］ Chern MC， Chuang VP， Cheng T， et al. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with inferior vena cava and right atrial tumors［J］. Cardiovasc Intervent Radiol， 2008， 31： 735 ?蛳 744.［12］ Grieco A， Pompili M， Caminiti G， et al. Prognostic factors for survival in patients with early?蛳 intermediate hepatocellular carcinoma undergoing non?蛳 surgical therapy： comparison of Okuda， CLIP， and BCLC staging systems in a single Italian centre［J］. Gut， 2005， 54： 411 ?蛳 418.［13］ Kiely JM， Rilling WS， Touzios JG， et al. Chemoembolization in patients at high risk： results and complications［J］. J Vasc Interv Radiol， 2006， 17： 47 ?蛳 53.［14］ 董家鸿， 郑树森， 陈孝平， 等． 肝切除术前肝脏储备功能评估的专家共识（2011版）［J］． 中华消化外科杂志， 2011， 10： 20 ?蛳 25．［15］ Chen MS， Li JQ， Zhang YQ， et al. High?蛳 dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma［J］. World J Gastroenterol， 2002， 8： 74 ?蛳 78.

相似文献/References:

[1]叶更新,曾文,杜德坤,等.肝动脉栓塞与经皮碘油标记酒精注射联合治疗晚期肝癌[J].介入放射学杂志,1996,(01):42.
[2]施长杲,吕维富,鲁 东,等.肝动脉化疗栓塞术后并发肝脓肿５例治疗分析[J].介入放射学杂志,2011,(04):273.
　SHI Chang-gao,LV Wei-fu,LU Dong,et al.The treatment of liver abscess occurred after transcatheter arterial chemoembolization report of five cases[J].journal interventional radiology,2011,(03):273.
[3]刘纪营,马 南,管 生,等. 预防性应用抗生素的不同方法对介入治疗并发肝脓肿的影响[J].介入放射学杂志,2013,(06):474.
　LIU Ji? ying,MA Nan,GUAN Sheng,et al. The influence of different using methods of antibiotic prophylaxis on the occurrence of liver abscess after transcatheter hepatic arterial chemoembolization[J].journal interventional radiology,2013,(03):474.
[4]宿敬存,赵 卫,胡继红,等.TACE联合RFA及自体细胞因子诱导的杀伤细胞肝动脉灌注治疗原发性肝癌的临床研究[J].介入放射学杂志,2017,(01):24.
　SU Jing- cun,ZHAO Wei,HU Ji- hong,et al.TACE combined with RFA and hepatic artery infusion of autologous cytokine- induced killer cells for the treatment of hepatocellular carcinoma： a clinical study [J].journal interventional radiology,2017,(03):24.
[5]杨晓红,赵广生,袁 琳,等.明胶海绵微粒联合TACE治疗原发性肝癌的护理[J].介入放射学杂志,2013,(02):163.
　YANG Xiao? hong,ZHAO Guang? sheng,YUAN Lin,et al.The nursing care for patients of primary hepatocellular carcinoma receiving TACE together with gelatin sponge particles[J].journal interventional radiology,2013,(03):163.
[6]冯 超,赵剑波,陈 勇,等.原发性肝癌切除术后预防性经肝动脉介入治疗：肝动脉化疗栓塞术和化疗灌注术比较[J].介入放射学杂志,2014,(08):679.
　FENG Chao,ZHAO Jian bo,CHEN Yong,et al.The preventive transhepatic interventional therapy for primary liver cancer after surgical resection： comparison study between TACE and TAI[J].journal interventional radiology,2014,(03):679.
[7]徐国斌,易广新,熊斌,等.原发性肝癌术后早期肝内复发转移36例的介入治疗[J].介入放射学杂志,2013,(04):325.
　XU Guo? bin,YI Guang? xin,XIONG Bin,et al.Interventional treatment of early intrahepatic recurrence or metastasis of primary liver carcinoma after surgical resection： initial experience of 36 cases[J].journal interventional radiology,2013,(03):325.
[8]孟庆雯,李勇,胡宝山,等.经肝动脉化疗栓塞与射频消融和无水乙醇注入对大肝癌的疗效评价及预后分析[J].介入放射学杂志,2013,(08):646.
　MENG Qing? wen,LI Yong,HU Bao? shan,et al.ranscatheter arterial chemoembolization combined with radiofrequency ablation and percutaneous ethanol injection for large hepatocellular carcinoma： therapeutic evaluation and prognosis analysis[J].journal interventional radiology,2013,(03):646.
[9]臧 爽,徐 阳,梁松年.原发性肝癌患者经肝动脉化疗栓塞术后住院天数影响因素的多元线性回归分析[J].介入放射学杂志,2015,(01):80.
　ZANG Shuang,XU Yang,LIANG Song nian..Multiple linear regression analysis of factors related to the hospitalization days in HCC patients after transcatheter hepatic arterial chemoembolization[J].journal interventional radiology,2015,(03):80.
[10]王立静,苗同国,宁更献,等.肝动脉化疗栓塞术对原发性肝癌患者T淋巴细胞亚群的影响 [J].介入放射学杂志,2015,(02):165.
　WANG Li jing,MIAO Tong guo,NING Geng xian,et al.The influence of TACE on T lymphocyte subsets in patients with primary liver cancer[J].journal interventional radiology,2015,(03):165.

备注/Memo

备注/Memo:
（收稿日期：２０１2-1０-1０）
更新日期/Last Update: